Ecovyst Inc (ECVT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Ecovyst Inc (Ecovyst) formerly PQ Group Holdings Inc, is an integrated provider of sulfuric acid products and services. The company's main activities include the production and recycling of virgin and regenerated sulfuric acid. Its major services encompass sulfuric acid recycling, chemical waste handling, and ex-situ catalyst activation for the refining and petrochemical industries. The company's products and services are utilized by the North American refining industry, particularly in the production of alkylate for cleaner-burning gasoline, as well as in various mining and industrial applications. The company operates through a strategically located network of nine manufacturing facilities across the US, ensuring efficient delivery service. The company's products serve customers in industries such as mining, electronics, automotive, water treatment, and agriculture. Ecovyst is headquartered in Wayne, Pennsylvania, the US.Ecovyst Inc Key Recent Developments
- Apr 20, 2026: Ecovyst to Host First Quarter 2026 Earnings Conference Call and Webcast on Tuesday, May 5, 2026
- Feb 26, 2026: Ecovyst Reports Fourth Quarter and Full Year 2025 Results
- Nov 04, 2025: Ecovyst Reports Third Quarter 2025 Results and Updates Guidance
- Sep 11, 2025: Ecovyst Agrees to Sell Advanced Materials & Catalyst Segment to Technip Energies
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
- Veracyte Inc Company Overview
- Veracyte Inc Company Snapshot
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc - Pipeline Analysis Overview
- Veracyte Inc - Key Facts
- Veracyte Inc - Major Products and Services
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Pipeline Products Overview
- Afirma - Risk of Recurrence
- Afirma - Risk of Recurrence Product Overview
- Afirma - Thyroid Cancer Staging/ Prognosis Test
- Afirma - Thyroid Cancer Staging/ Prognosis Test Product Overview
- Afirma Xpression Atlas - Pulmonology
- Afirma Xpression Atlas - Pulmonology Product Overview
- AI Based Liquid Biopsy Assay - Solid Tumors
- AI Based Liquid Biopsy Assay - Solid Tumors Product Overview
- BronchoGen Test
- BronchoGen Test Product Overview
- Comprehensive Genomic Profiling Test
- Comprehensive Genomic Profiling Test Product Overview
- Disease Diagnosis Device
- Disease Diagnosis Device Product Overview
- Envisia - Disease Progression Test
- Envisia - Disease Progression Test Product Overview
- Envisia - Rx Response Test
- Envisia - Rx Response Test Product Overview
- Envisia Genomic Classifier
- Envisia Genomic Classifier Product Overview
- Envisia IVD Test
- Envisia IVD Test Product Overview
- MRD Test - Muscle-Invasive Bladder Cancer
- MRD Test - Muscle-Invasive Bladder Cancer Product Overview
- nCounter Dx LymphMark Assay
- nCounter Dx LymphMark Assay Product Overview
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test Product Overview
- Percepta Atlas
- Percepta Atlas Product Overview
- Percepta Nasal Swab Test
- Percepta Nasal Swab Test Product Overview
- Percepta Nasal Swab Test Clinical Trial
- Prosigna NGS Test
- Prosigna NGS Test Product Overview
- Veracyte Inc - Key Competitors
- Veracyte Inc - Key Employees
- Veracyte Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Veracyte Inc, Recent Developments
- Jul 09, 2026: Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
- Jun 01, 2026: ASCO26: Data highlights test benefit in breast cancer treatment planning and earlier detection
- Jun 01, 2026: Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
- May 29, 2026: Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
- May 22, 2026: Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
- May 21, 2026: OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
- May 19, 2026: Veracyte to Participate in Upcoming Investor Conferences
- Apr 28, 2026: Veracyte Presents Decipher Data at AUA 2026 to Advance Personalized Urologic Cancer Care
- Feb 24, 2026: Veracyte to Highlight Extensive Decipher Data at 2026 ASCO GU Symposium
- Feb 19, 2026: Veracyte Announces Plans to Participate in Upcoming Investor Conferences
- Appendix
- Methodology
- About the Analyst
- Contact the Publisher
- Disclaimer
- Veracyte Inc Pipeline Products and Ongoing Clinical Trials Overview
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Indication
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc, Key Facts
- Veracyte Inc, Major Products and Services
- Veracyte Inc Number of Pipeline Products by Development Stage
- Veracyte Inc Pipeline Products Summary by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
- Veracyte Inc Ongoing Clinical Trials Summary
- Afirma - Risk of Recurrence - Product Status
- Afirma - Risk of Recurrence - Product Description
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Status
- Afirma - Thyroid Cancer Staging/ Prognosis Test - Product Description
- Afirma Xpression Atlas - Pulmonology - Product Status
- Afirma Xpression Atlas - Pulmonology - Product Description
- AI Based Liquid Biopsy Assay - Solid Tumors - Product Status
- AI Based Liquid Biopsy Assay - Solid Tumors - Product Description
- BronchoGen Test - Product Status
- BronchoGen Test - Product Description
- Comprehensive Genomic Profiling Test - Product Status
- Comprehensive Genomic Profiling Test - Product Description
- Disease Diagnosis Device - Product Status
- Disease Diagnosis Device - Product Description
- Envisia - Disease Progression Test - Product Status
- Envisia - Disease Progression Test - Product Description
- Envisia - Rx Response Test - Product Status
- Envisia - Rx Response Test - Product Description
- Envisia Genomic Classifier - Product Status
- Envisia Genomic Classifier - Product Description
- Envisia IVD Test - Product Status
- Envisia IVD Test - Product Description
- MRD Test - Muscle-Invasive Bladder Cancer - Product Status
- MRD Test - Muscle-Invasive Bladder Cancer - Product Description
- nCounter Dx LymphMark Assay - Product Status
- nCounter Dx LymphMark Assay - Product Description
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Status
- nCounter FLEX Analysis System - Idiopathic Pulmonary Fibrosis Test - Product Description
- Percepta Atlas - Product Status
- Percepta Atlas - Product Description
- Percepta Nasal Swab Test - Product Status
- Percepta Nasal Swab Test - Product Description
- Percepta Nasal Swab Test - Clinical Utility of Management of Patients With CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier
- Prosigna NGS Test - Product Status
- Prosigna NGS Test - Product Description
- Veracyte Inc, Key Employees
- Veracyte Inc, Other Locations
- Veracyte Inc, Subsidiaries
- Glossary
- Veracyte Inc Pipeline Products by Equipment Type
- Veracyte Inc Pipeline Products by Development Stage
- Veracyte Inc Ongoing Clinical Trials by Trial Status
